teaser
Lundbeck today announced the joint decision with its partner Solvay Pharmaceuticals, BV (Solvay) to stop all joint R&D activities for Solvay’s compound bifeprunox in development for maintenance treatment of schizophrenia.
The companies made this decision after evaluating the recent results from an interim analysis of pooled data intended for a possible extension of the ongoing clinical phase III trial programme. Efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia. Therefore, Lundbeck and Solvay judge that it would be futile to continue the studies.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
